A critical review of bioactive glasses and glass–ceramics in cancer therapy
Source abstract
Abstract
Abstract There is an ongoing profound shift in using glass as a primarily passive material to one that instills active properties. We believe and demonstrate that bioactive glasses (BGs) and glass–ceramics (BGCs) as functional biomaterials for cancer therapy can transform the world of healthcare in the 21st century. Melt/gel‐derived BGs and BGCs can carry many exotic elements, including less common rare‐earth, and trigger highly efficient anticancer properties via the combination of radiotherapy, photothermal therapy, magnetic hyperthermia, along with drug or therapeutic ions delivery. The addition of these dopants modifies the bioactivity, imparts novel functionalities, and induces specific biological effects that are not achievable using other classes of biomaterials. In this paper, we have briefly reviewed and discussed the current knowledge on promising compositions, processing parameters, and applications of BGs and BGCs in treating cancer. We also envisage the need for further research on this particular, unique class of BGs and BGCs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Luminescence Properties of Advanced Materials · Glass properties and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Materials Science and Engineering Sharif University of Technology Tehran Iran
Northeastern Laboratory for Evaluation and Development of Biomaterials (CERTBIO) Federal University of Campina Grande Campina Grande Paraíba Brazil
Institute of Materials Physics and Engineering Department of Applied Science and Technology Politecnico di Torino Torino Italy
References (100+)
Show source-provided references
1. 10.1002/jcp.2981910.1002/jcp.29819 ↗
2. 10.1016/j.jconrel.2020.06.03810.1016/j.jconrel.2020.06.038 ↗
3. Delivery of melittin‐loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti‐cancer effect
4. 10.3390/bioengineering703009110.3390/bioengineering7030091 ↗
5. 10.3389/fchem.2020.0082910.3389/fchem.2020.00829 ↗
6. 10.1007/s10853-017-0804-410.1007/s10853-017-0804-4 ↗
7. 10.1039/9781782622017-0002710.1039/9781782622017-00027 ↗
8. 10.1039/978178262201710.1039/9781782622017 ↗
9. 10.3390/jfb901002510.3390/jfb9010025 ↗
10. 10.1016/j.drudis.2018.05.02710.1016/j.drudis.2018.05.027 ↗
11. 10.1177/039139881987628610.1177/0391398819876286 ↗
12. 10.1007/s10856-021-06626-310.1007/s10856-021-06626-3 ↗
13. 10.3390/ma1405113110.3390/ma14051131 ↗
14. 10.1038/s41413-021-00139-z10.1038/s41413-021-00139-z ↗
15. 10.1016/j.jallcom.2021.15901310.1016/j.jallcom.2021.159013 ↗
16. 10.1021/am404574t10.1021/am404574t ↗
17. 10.1016/j.cclet.2020.03.00110.1016/j.cclet.2020.03.001 ↗
18. 10.1080/1061186X.2018.151902910.1080/1061186X.2018.1519029 ↗
19. 10.1002/adtp.20200021210.1002/adtp.202000212 ↗
20. 10.1111/jace.1786110.1111/jace.17861 ↗
21. An analysis of glass‐ceramic research and commercialization
22. Pontieri GM · 2009
23. 10.7150/ijms.363510.7150/ijms.3635 ↗
24. 10.1038/jid.2011.41110.1038/jid.2011.411 ↗
25. 10.1038/nrc300710.1038/nrc3007 ↗
26. 10.1038/nature0846710.1038/nature08467 ↗
27. I‐125 Seeds. Available online:https://www.eyephysics.com/PS/PS6/UserGuide/OrderSeeds.html. Accessed 17 June 2022.
28. 10.2967/jnumed.116.18633810.2967/jnumed.116.186338 ↗
29. 10.1016/j.jmir.2019.11.08810.1016/j.jmir.2019.11.088 ↗
30. 10.1007/s00262-019-02418-510.1007/s00262-019-02418-5 ↗
31. 10.1097/MD.000000000000125310.1097/MD.0000000000001253 ↗
32. Radiation Therapy for Bone Cancer. Available online:https://www.cancer.org/treatment/treatments‐and‐side‐effects/treatment‐types/radiation.html. Accessed 13 December 2020.
33. 10.1148/rg.201514029310.1148/rg.2015140293 ↗
34. Half‐life of iodine‐125
35. 10.1111/j.2041-1294.2010.00001.x10.1111/j.2041-1294.2010.00001.x ↗
36. 10.1039/c1cp21764j10.1039/c1cp21764j ↗
37. 10.1016/j.actbio.2011.03.01610.1016/j.actbio.2011.03.016 ↗
38. 10.1002/9781118346457.ch1310.1002/9781118346457.ch13 ↗
39. 10.1016/j.nucmedbio.2020.09.00510.1016/j.nucmedbio.2020.09.005 ↗
40. 10.4028/www.scientific.net/KEM.94-95.18110.4028/www.scientific.net/KEM.94-95.181 ↗
41. 10.1016/B978-0-08-102196-5.00010-010.1016/B978-0-08-102196-5.00010-0 ↗
42. Day DE · 1988
43. BoosG ThirwellM BlanchardR CryipsC HerbaM GonzalesL et al.Y‐radioactive glasses for treatment of liver cancer. In:Proceedings of the 25th annual meeting of the American Society Clinical Oncology San Francisco CA USA;1989. p.21–3.
44. Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery. Available online:https://clinicaltrials.gov/ct2/show/NCT00039078. Accessed on 1 December 2021.
45. 10.1002/lt.2003610.1002/lt.20036 ↗
46. BretcanuO EvansI.Glasses for treatment of liver cancer by radioembolization. In:Biocompatible glasses.Cham:Springer;2016. p.267–83.10.1007/978-3-319-44249-5_11 ↗
47. 10.1088/2057-1976/ab36c210.1088/2057-1976/ab36c2 ↗
48. 10.1088/1361-6560/abf38a10.1088/1361-6560/abf38a ↗
49. 10.1186/s40658-022-00447-110.1186/s40658-022-00447-1 ↗
50. 10.1016/j.clcc.2015.02.00210.1016/j.clcc.2015.02.002 ↗
51. 10.2196/1154510.2196/11545 ↗
52. 10.1590/S1516-1439200300020000310.1590/S1516-14392003000200003 ↗
53. 10.1016/j.pnucene.2008.01.00710.1016/j.pnucene.2008.01.007 ↗
54. 10.1007/s10856-006-9681-010.1007/s10856-006-9681-0 ↗
55. 10.1007/s10856-007-3163-x10.1007/s10856-007-3163-x ↗
56. 10.1002/jbm.1004710.1002/jbm.10047 ↗
57. NogueiraLB CamposTPR.Nuclear characterization of radioactive bioglass seed for brachytherapy studies.M&C 2011: International conference on mathematics and computational methods applied to nuclear science and engineering Brazil.2011.
58. 10.1007/s10971-015-3900-410.1007/s10971-015-3900-4 ↗
59. 10.1016/j.msec.2020.11159510.1016/j.msec.2020.111595 ↗
60. 10.1016/j.apradiso.2012.12.00210.1016/j.apradiso.2012.12.002 ↗
61. 10.1097/MD.000000000000109810.1097/MD.0000000000001098 ↗
62. 10.1039/C0JM02179B10.1039/C0JM02179B ↗
63. 10.1016/j.micromeso.2008.08.04610.1016/j.micromeso.2008.08.046 ↗
64. 10.1002/chem.20100013710.1002/chem.201000137 ↗
65. 10.1186/s12891-018-1977-y10.1186/s12891-018-1977-y ↗
66. 10.1088/1758-5090/8/3/03500510.1088/1758-5090/8/3/035005 ↗
67. 10.3390/ma1110188010.3390/ma11101880 ↗
68. 10.1016/j.apmt.2020.10057810.1016/j.apmt.2020.100578 ↗
69. 10.1016/j.actbio.2018.04.01410.1016/j.actbio.2018.04.014 ↗
70. 10.1155/2015/83920710.1155/2015/839207 ↗
71. 10.1002/adtp.20190012410.1002/adtp.201900124 ↗
72. 10.1016/j.addr.2011.09.00610.1016/j.addr.2011.09.006 ↗
73. 10.1002/adfm.20160598510.1002/adfm.201605985 ↗
74. 10.1016/j.msec.2017.03.28810.1016/j.msec.2017.03.288 ↗
75. 10.1016/j.jinorgbio.2019.11088710.1016/j.jinorgbio.2019.110887 ↗
76. 10.2147/IJN.S25434410.2147/IJN.S254344 ↗
77. 10.1016/j.jcis.2020.06.12210.1016/j.jcis.2020.06.122 ↗
78. 10.1039/C9RA09349D10.1039/C9RA09349D ↗
79. 10.1016/j.ceramint.2020.08.08310.1016/j.ceramint.2020.08.083 ↗
80. 10.1039/c3dt50659b10.1039/c3dt50659b ↗
81. 10.1021/ja200328s10.1021/ja200328s ↗
82. 10.1039/c3tb20275e10.1039/c3tb20275e ↗
83. 10.1016/j.colsurfb.2017.09.05110.1016/j.colsurfb.2017.09.051 ↗
84. 10.1016/j.ceramint.2020.01.08610.1016/j.ceramint.2020.01.086 ↗
85. 10.1016/j.msec.2016.05.01910.1016/j.msec.2016.05.019 ↗
86. 10.1088/1748-605X/aba7d510.1088/1748-605X/aba7d5 ↗
87. 10.1021/acsami.5b0159210.1021/acsami.5b01592 ↗
88. 10.7150/thno.2267910.7150/thno.22679 ↗
89. 10.1080/1061186X.2017.135872910.1080/1061186X.2017.1358729 ↗
90. 10.1039/C5NR00642B10.1039/C5NR00642B ↗
91. 10.1016/j.jconrel.2012.07.01110.1016/j.jconrel.2012.07.011 ↗
92. 10.1002/anie.20130861910.1002/anie.201308619 ↗
93. 10.1021/tx300166u10.1021/tx300166u ↗
94. 10.1039/c2jm30501a10.1039/c2jm30501a ↗
95. 10.1039/c0jm03421e10.1039/c0jm03421e ↗
96. 10.1016/j.micromeso.2008.12.01910.1016/j.micromeso.2008.12.019 ↗
97. 10.1021/cm901259n10.1021/cm901259n ↗
98. 10.1016/j.cis.2017.03.00810.1016/j.cis.2017.03.008 ↗
99. 10.1039/c0nr00039f10.1039/c0nr00039f ↗
100. 10.3390/nano707018910.3390/nano7070189 ↗